MSLE Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MSLE Stock 12 Month Forecast
Average Price Target
$24.60
▲(184.06% Upside)
| Highest Price Target$40.00 | Average Price Target$24.60 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$20
Buy
130.95%
Upside
Reiterated
10/01/26
LifeSci Capital
$22
Buy
154.04%
Upside
Reiterated
09/30/26
H.C. Wainwright
$18
Buy
107.85%
Upside
Reiterated
09/25/26
Oppenheimer
$40
Buy
361.89%
Upside
Reiterated
08/14/26
Guggenheim
$23
Buy
165.59%
Upside
Reiterated
07/09/26
Canaccord Genuity
$13.34
Buy
54.05%
Upside
Initiated
05/21/26
Leede Financial
$16
Buy
84.76%
Upside
Reiterated
03/11/26
The Canadian biotech stock will beat the market, analyst saysLoe said the Ontario-based rare-disease drug developer recently reported updated interim Phase II data from its TRAILHEAD trial, a 30-patient adult DMD study evaluating SAT-3247, an orally active small-molecule drug designed to inhibit adaptor-associated protein kinase 1 (AAK1).
Cantor Fitzgerald
―
Buy
―
Initiated
03/11/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$20
Buy
130.95%
Upside
Reiterated
10/01/26
LifeSci Capital
$22
Buy
154.04%
Upside
Reiterated
09/30/26
H.C. Wainwright
$18
Buy
107.85%
Upside
Reiterated
09/25/26
Oppenheimer
$40
Buy
361.89%
Upside
Reiterated
08/14/26
Guggenheim
$23
Buy
165.59%
Upside
Reiterated
07/09/26
Canaccord Genuity
$13.34
Buy
54.05%
Upside
Initiated
05/21/26
Leede Financial
$16
Buy
84.76%
Upside
Reiterated
03/11/26
The Canadian biotech stock will beat the market, analyst saysLoe said the Ontario-based rare-disease drug developer recently reported updated interim Phase II data from its TRAILHEAD trial, a 30-patient adult DMD study evaluating SAT-3247, an orally active small-molecule drug designed to inhibit adaptor-associated protein kinase 1 (AAK1).
Cantor Fitzgerald
―
Buy
―
Initiated
03/11/26
Best Analysts Covering Satellos Bioscience
3 Months
Success Rate
9/15 ratings generated profit
Average Return
+21.18%
Copying Arthur He CFA's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +21.18% per trade.
1 Year
Success Rate
10/15 ratings generated profit
Average Return
+23.87%
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +23.87% per trade.
2 Years
Success Rate
12/15 ratings generated profit
Average Return
+50.41%
Copying Arthur He CFA's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +50.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MSLE Analyst Recommendation Trends
Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
7
6
7
9
8
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
6
7
9
8
Each month's total comprises the sum of three months' worth of ratings.
MSLE Financial Forecast
MSLE Stock Forecast FAQ
What is MSLE’s average 12-month price target, according to analysts?
Based on analyst ratings, Satellos Bioscience’s 12-month average price target is 24.60.
What is MSLE’s upside potential, based on the analysts’ average price target?
Satellos Bioscience has 184.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MSLE a Buy, Sell or Hold?
Satellos Bioscience has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Satellos Bioscience’s price target?
The average price target for Satellos Bioscience is 24.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $18.00. The average price target represents 184.06% Increase from the current price of $8.66.
The highest analyst price target is $40.00 ,the lowest forecast is $18.00. The average price target represents 184.06% Increase from the current price of $8.66.
What do analysts say about Satellos Bioscience?
Satellos Bioscience’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of MSLE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.